Vakura T-cell tumors, senge isiri-Hodgkin T-cell lymphoma, inokonzeresa uye haina mishonga, uye varwere vanowanzo kuve nehurombo hwekufungidzira. Munguva pfupi yapfuura, "Zvisikwa" zvakateedzana zvinyorwa zviviri zvakaburitsa dudziro nyowani yehutachiona hweiyo isiri Hodgkin's T-cell lymphoma, nekudaro ichipa nzira nyowani yekusimudzira kwakanaka kwemishonga mitsva yerudzi urwu rweyakaipa lymphoma.
Muchidzidzo chekutanga, boka reWartewig rakashandisa fusion protein ITK-SYK kugadzira transgenic mouse model ye late-start T-cell lymphoma (Nature. Doi: 10.1038 / nature24649), uye yakaona kuti imwe kana kaviri kopi yePDCD1. gene encoding iyo PD1 protein yakabviswa. T cell lymphoma inopinda nekukurumidza kushanduka kwakashata uye inomhanyisa kufa kweiyo mbeva modhi. Mukuwedzera, kushandiswa kwePD1 kana PD-L1 inhibitors kunogona kuunza zvakafanana. Iyo yakabatana nzira ndeyekuti PD1 kumusoro-inogadzirisa PTEN kutaura uye inhibits bundu rakashata rekuwedzera nzira PI3K.
Mune imwe nyaya, Maciocia et al. Yakaiswa chimeric antigen receptor T cell immunotherapy (CAR-T) therapy (Nat Med. Doi: 10.1038 / nm.4444) kugadzira masero eCAR-T anonyanya kunanga TRBC1 asi kwete TRBC2 Kurapa TRBC1-positive T-cell carcinoma. Paunenge uchiuraya masero ebundu, uchisiya akakwana T masero kurwisa hutachiona. Muedzo wekiriniki wenzira iyi uchatangwa zviri pamutemo muna 2018.
Musiki mukuru mupepeti Megan Cully akati izvo zvataurwa pamusoro apa zvakakosha zvinopa nzira nyowani yekurapa yekurapa kwevakakura T-cell malignancies uye kunyevera kuti aya mamota haana kukodzera kurapwa ne PD1 kana PDL1 inhibitors.
